Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study

Basit Öğe Kaydı
dc.authoridCOSAR, Arif Mansur/0000-0002-4472-2895
dc.authoridKarkucak, Murat/0000-0002-4348-8398
dc.contributor.authorCapkin, Erhan
dc.contributor.authorKarkucak, Murat
dc.contributor.authorCosar, Arif M.
dc.contributor.authorAk, Emel
dc.contributor.authorKaraca, Adem
dc.contributor.authorGokmen, Ferhat
dc.contributor.authorBudak, Bayram S.
dc.date.accessioned2025-01-27T20:14:48Z
dc.date.available2025-01-27T20:14:48Z
dc.date.issued2015
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAimTo retrospectively investigate and compare the effects of tumor necrosis factor alpha inhibitors (TNFi) on hepatic enzymes in ankylosing spondylitis (AS) patients. MethodsA retrospective analysis of the records of 94 AS (66 male, 28 female) patients using TNFi was performed. Patients' clinical data, Bath Ankylosing Spondylitis Disease Activity (BASDAI) scores, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were all examined. Liver function test (LFTs) results of patients before the treatment and 3, 6 and 12months after treatment with TNFi were investigated. Aspartate transaminase (AST) and alanine transaminase (ALT) levels were investigated as indicators of LFTs. ResultsThe TNFi drugs used were infliximab (n=28), adalimumab (n=32) and etanercept (n=34). Pre-treatment values of ESR, CRP and BASDAI scores were 28.320.1mm/h, 1.5 +/- 1.2ng/dL and 5.2 +/- 0.8, respectively. Following TNFi use there was a statistically significant decrease in disease activity score (P=0.001). There was a significant increase in LFT at the third month evaluation compared to the initial values, while the average value was within normal range (baseline AST 19.6 +/- 10.8U/L, ALT 19.1 +/- 6.4U/L, third month AST 31.3 +/- 21.6U/L, ALT 28.1 +/- 18.1U/L, P=0.001). Drug group comparison analysis revealed a significant difference in the adalimumab group value at the end of the first year, but no other significant difference in the data for the other months (P>0.05). No significant correlation was determined between initial disease activity scores and LFT. ConclusionTNFi use-associated rises in hepatic enzymes were determined compared to pre-treatment but the mean values remained within normal limits. Considering the cases in the literature, in daily practice patients must be carefully monitored for liver function before treatment and at follow-up.
dc.identifier.doi10.1111/1756-185X.12311
dc.identifier.endpage552
dc.identifier.issn1756-1841
dc.identifier.issn1756-185X
dc.identifier.issue5
dc.identifier.pmid24612551
dc.identifier.scopus2-s2.0-84931005522
dc.identifier.scopusqualityQ3
dc.identifier.startpage548
dc.identifier.urihttps://doi.org/10.1111/1756-185X.12311
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21206
dc.identifier.volume18
dc.identifier.wosWOS:000356367800010
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofInternational Journal of Rheumatic Diseases
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectalanine transaminase
dc.subjectankylosing spondylitis
dc.subjectaspartate transaminase
dc.subjectdisease activity
dc.subjectTNF inhibitors
dc.titleTreatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu